ASCO GI Symposium 2025: Focus on Liver Cancer
Stay up-to-date with the latest research and clinical updates on liver cancer from the 2025 ASCO GI Symposium.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Trial results show no significant benefit of adding chemoradiation to adjuvant chemotherapy in resected gallbladder cancer.
SBRT shows promise for liver tumor control, but hepatobiliary toxicity remains a concern.
Atezolizumab plus bevacizumab shows promising efficacy and tolerability for advanced HCC with Child-Pugh B cirrhosis.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.